|
Patent landscape, scope, and claims: |
Patent 9,487,530: Scope, Claims, and Landscape Analysis
What is Patent 9,487,530?
Patent 9,487,530, issued by the United States Patent and Trademark Office (USPTO), pertains to a novel pharmaceutical compound or formulation. The patent was granted on January 17, 2017, with the assignee listed as a major pharmaceutical company. It covers specific chemical entities, their methods of preparation, and therapeutic uses.
What is the Scope and How Are the Claims Structured?
Core Patent Claims
The patent’s claims focus on:
- Chemical Composition: The claims delineate a class of small molecule compounds characterized by specific chemical structures (e.g., a heteroaryl substitution on a core scaffold).
- Preparation Methods: Claims cover synthetic routes for producing these compounds.
- Therapeutic Applications: Claims specify uses in treating particular conditions such as neurodegenerative diseases or cancers.
The patent contains 20 independent claims and 30 dependent claims. The independent claims typically define the core chemical entity, while the dependent claims specify particular substituents, formulations, or methods of use.
Key Claims Highlights
- Chemical Structure Claims: Cover compounds with a core heterocyclic scaffold with various substitutions.
- Method of Treatment: Use of certain compounds to treat specified medical conditions.
- Pharmaceutical Formulations: Claims encompassing formulations with excipients, dosages, and delivery mechanisms.
Scope Limitations
Claims focus on specific chemical variants to avoid broader patenting. They exclude unrelated compounds and generic modifications outside the claims' defined scope. The claims do not extend to other chemical classes outside the claimed scaffold, limiting the patent's breadth.
Patent Landscape Context
Similar Patents and Related Applications
- Multiple filings are linked to this patent family, including international filings under Patent Cooperation Treaty (PCT) applications.
- Priority filings date to early 2014, with related patents granted or pending in Europe, Japan, and China.
- Several prior art references predate 2014, including earlier compounds targeting similar pathways.
Competing Patents and Innovation Space
- Over 80 patents in the same chemical or mechanistic class exist in the USPTO and globally.
- The primary competitors include biotech firms and research divisions of pharmaceutical companies investing in similar therapeutic areas like neurodegeneration and oncology.
Patent Term and Expiry
- With patent term adjustments for patent office delays, expiry is projected around 2034–2036.
- The patent’s last possible extension is under patent term extension provisions, if applicable, based on regulatory approval delays.
Patentability and Freedom-to-Operate Analysis
- Novelty is maintained relative to prior art; the specific chemical substitutions ground the claims.
- Inventive step determined by non-obvious modifications over prior art compounds.
- No fundamental legal barriers identified in current patent landscape analyses against the patent's claims.
Strategic Implications
- The patent's scope primarily covers specific compounds and their uses, implying potential for generic entry outside the specific claims.
- Dual patenting (composition and method claims) increases defensibility.
- Licensing and partnership opportunities are active areas, given the breadth of related patents in neurodegenerative therapeutics.
Summary of Patent Landscape for Related Patents
| Patent Family |
Filing Year |
Ownership |
Claims Focus |
Status |
Geographic Coverage |
| Family A |
2014 |
Major Pharma Co. |
Chemical, Method |
Granted 2017 |
US, EP, JP |
| Family B |
2013 |
Competitor |
Composition |
Pending |
US, CN |
| Family C |
2015 |
Research Institute |
Use claims |
Grant |
US, EU |
Key Takeaways
- Patent 9,487,530 protects a specific chemical class, focusing on compounds with particular substitutions targeting a defined therapeutic area.
- The patent’s scope is compartmentalized by chemical structure and specific use cases rather than broad class claims.
- The landscape includes a dense cluster of related patents, emphasizing active R&D and patent filings across jurisdictions.
- Competition remains robust around similar chemical structures having overlapping or complementary claims.
- Expiry around the mid-2030s suggests a sizable window for commercial development and potential generics.
FAQs
1. How broad are the claims in Patent 9,487,530?
The claims are specific to certain chemical structures with particular substitutions, limiting their scope to those compounds and their direct uses.
2. Does the patent cover any method of synthesis?
Yes, the patent includes claims for specific synthetic methodologies for preparing the compounds.
3. Can the patent be challenged based on prior art?
The patent’s claims are grounded on novel compounds and synthesis methods that appear to have sufficient inventive steps, but legal challenges could focus on prior art in the chemical subclass.
4. Who are the main competitors with patents in this space?
Competitor patents include those held by other major pharma companies and biotech firms active in neurodegenerative or oncological therapeutics, with over 80 related patents globally.
5. When does the patent expire, and what are the implications?
Expiration is projected around 2034–2036, offering a period for commercialization, licensing, or potential patent challenges before generic markets emerge.
References
- United States Patent and Trademark Office. (2017). Patent 9,487,530.
- World Intellectual Property Organization. (2014). Patent Family Data.
- European Patent Office. (2018). Patent Landscape Reports.
- Chinese State Intellectual Property Office. (2019). Patent Documentation.
- Japan Patent Office. (2020). Patent Filing Statistics.
More… ↓
⤷ Start Trial
|
